Literature DB >> 26715289

Effect of 3-bromopyruvate acid on the redox equilibrium in non-invasive MCF-7 and invasive MDA-MB-231 breast cancer cells.

Ewa Kwiatkowska1, Martyna Wojtala1, Agnieszka Gajewska1, Mirosław Soszyński1, Grzegorz Bartosz2, Izabela Sadowska-Bartosz3.   

Abstract

Novel approaches to cancer chemotherapy employ metabolic differences between normal and tumor cells, including the high dependence of cancer cells on glycolysis ("Warburg effect"). 3-Bromopyruvate (3-BP), inhibitor of glycolysis, belongs to anticancer drugs basing on this principle. 3-BP was tested for its capacity to kill human non-invasive MCF-7 and invasive MDA-MB-231 breast cancer cells. We found that 3-BP was more toxic for MDA-MB-231 cells than for MCF-7 cells. In both cell lines, a statistically significant decrease of ATP and glutathione was observed in a time- and 3-BP concentration-dependent manner. Transient increases in the level of reactive oxygen species and reactive oxygen species was observed, more pronounced in MCF-7 cells, followed by a decreasing tendency. Activities of glutathione peroxidase, glutathione reductase (GR) and glutathione S-transferase (GST) decreased in 3-BP treated MDA-MB-231 cells. For MCF-7 cells decreases of GR and GST activities were noted only at the highest concentration of 3-BP.These results point to induction of oxidative stress by 3-BP via depletion of antioxidants and inactivation of antioxidant enzymes, more pronounced in MDA-MB-231 cells, more sensitive to 3-BP.

Entities:  

Keywords:  3-bromopyruvate; Breast tumor; Free radicals; MCF-7 cells; MDA-MB-231 cells; Oxidative stress

Mesh:

Substances:

Year:  2015        PMID: 26715289     DOI: 10.1007/s10863-015-9637-5

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   2.945


  41 in total

1.  The antitumor agent 3-bromopyruvate has a short half-life at physiological conditions.

Authors:  Matthew Glick; Perry Biddle; Josh Jantzi; Samantha Weaver; Doug Schirch
Journal:  Biochem Biophys Res Commun       Date:  2014-08-21       Impact factor: 3.575

2.  3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effects.

Authors:  S M El Sayed; R M Abou El-Magd; Y Shishido; S P Chung; T H Diem; T Sakai; H Watanabe; S Kagami; K Fukui
Journal:  J Bioenerg Biomembr       Date:  2012-02-09       Impact factor: 2.945

Review 3.  Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug.

Authors:  Simone Cardaci; Enrico Desideri; Maria Rosa Ciriolo
Journal:  J Bioenerg Biomembr       Date:  2012-02       Impact factor: 2.945

4.  Reactive oxygen species: destroyers or messengers?

Authors:  Grzegorz Bartosz
Journal:  Biochem Pharmacol       Date:  2008-11-24       Impact factor: 5.858

5.  E3 ubiquitin ligase APC/C-Cdh1 accounts for the Warburg effect by linking glycolysis to cell proliferation.

Authors:  Angeles Almeida; Juan P Bolaños; Salvador Moncada
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

Review 6.  Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting.

Authors:  Shanmugasundaram Ganapathy-Kanniappan; Rani Kunjithapatham; Jean-Francois Geschwind
Journal:  Anticancer Res       Date:  2013-01       Impact factor: 2.480

7.  MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors.

Authors:  Kivanç Birsoy; Tim Wang; Richard Possemato; Omer H Yilmaz; Catherine E Koch; Walter W Chen; Amanda W Hutchins; Yetis Gultekin; Tim R Peterson; Jan E Carette; Thijn R Brummelkamp; Clary B Clish; David M Sabatini
Journal:  Nat Genet       Date:  2012-12-02       Impact factor: 38.330

8.  Targeting tumour energy metabolism potentiates the cytotoxicity of 5-aminolevulinic acid photodynamic therapy.

Authors:  J P Golding; T Wardhaugh; L Patrick; M Turner; J B Phillips; J I Bruce; S G Kimani
Journal:  Br J Cancer       Date:  2013-07-16       Impact factor: 7.640

9.  Hexokinase II inhibitor, 3-BrPA induced autophagy by stimulating ROS formation in human breast cancer cells.

Authors:  Qianwen Zhang; Yuanyuan Zhang; Pei Zhang; Zhenhua Chao; Fei Xia; Chenchen Jiang; Xudong Zhang; Zhiwen Jiang; Hao Liu
Journal:  Genes Cancer       Date:  2014-03

10.  Targeting glycolysis by 3-bromopyruvate improves tamoxifen cytotoxicity of breast cancer cell lines.

Authors:  Yasmin M Attia; Hanan S El-Abhar; Mahmoud M Al Marzabani; Samia A Shouman
Journal:  BMC Cancer       Date:  2015-11-03       Impact factor: 4.430

View more
  17 in total

1.  Impaired mitochondrial functions contribute to 3-bromopyruvate toxicity in primary rat and mouse hepatocytes.

Authors:  Ondřej Sobotka; René Endlicher; Zdeněk Drahota; Otto Kučera; David Rychtrmoc; Marjan Raad; Khurum Hakeem; Zuzana Červinková
Journal:  J Bioenerg Biomembr       Date:  2016-08-16       Impact factor: 2.945

2.  Allele-specific interaction between glutathione peroxidase 1 and manganese superoxide dismutase affects the levels of Bcl-2, Sirt3 and E-cadherin.

Authors:  Dede N Ekoue; Soumen Bera; Emmanuel Ansong; Peter C Hart; Sofia Zaichick; Frederick E Domann; Marcelo G Bonini; Alan M Diamond
Journal:  Free Radic Res       Date:  2017-07-04

Review 3.  Metabolic changes in triple negative breast cancer-focus on aerobic glycolysis.

Authors:  J R Dev Arundhathi; Sandeep R Mathur; Ajay Gogia; S V S Deo; Purusottam Mohapatra; Chandra Prakash Prasad
Journal:  Mol Biol Rep       Date:  2021-05-28       Impact factor: 2.316

Review 4.  Mitochondrial VDAC1: A Key Gatekeeper as Potential Therapeutic Target.

Authors:  Amadou K S Camara; YiFan Zhou; Po-Chao Wen; Emad Tajkhorshid; Wai-Meng Kwok
Journal:  Front Physiol       Date:  2017-06-30       Impact factor: 4.566

5.  Epigenetically regulated Fibronectin leucine rich transmembrane protein 2 (FLRT2) shows tumor suppressor activity in breast cancer cells.

Authors:  Hansol Bae; Byungtak Kim; Hyunkyung Lee; Seungyeon Lee; Han-Sung Kang; Sun Jung Kim
Journal:  Sci Rep       Date:  2017-03-21       Impact factor: 4.379

Review 6.  Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer.

Authors:  Nicholas S Akins; Tanner C Nielson; Hoang V Le
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

7.  A Kelch domain-containing KLHDC7B and a long non-coding RNA ST8SIA6-AS1 act oppositely on breast cancer cell proliferation via the interferon signaling pathway.

Authors:  Gookjoo Jeong; Hansol Bae; Dawoon Jeong; Juyeon Ham; Sungbin Park; Hyeon Woo Kim; Han-Sung Kang; Sun Jung Kim
Journal:  Sci Rep       Date:  2018-08-27       Impact factor: 4.379

8.  Single Nucleotide Polymorphisms in MIR143 Contribute to Protection Against Non-Hodgkin Lymphoma (NHL) in Caucasian Populations.

Authors:  Gabrielle Bradshaw; Larisa M Haupt; Eunise M Aquino; Rodney A Lea; Heidi G Sutherland; Lyn R Griffiths
Journal:  Genes (Basel)       Date:  2019-02-27       Impact factor: 4.096

Review 9.  Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment.

Authors:  Tengjiao Fan; Guohui Sun; Xiaodong Sun; Lijiao Zhao; Rugang Zhong; Yongzhen Peng
Journal:  Cancers (Basel)       Date:  2019-03-06       Impact factor: 6.639

10.  Characterization of inorganic phosphate transport in the triple-negative breast cancer cell line, MDA-MB-231.

Authors:  Thais Russo-Abrahão; Marco Antônio Lacerda-Abreu; Tainá Gomes; Daniela Cosentino-Gomes; Ayra Diandra Carvalho-de-Araújo; Mariana Figueiredo Rodrigues; Ana Carolina Leal de Oliveira; Franklin David Rumjanek; Robson de Queiroz Monteiro; José Roberto Meyer-Fernandes
Journal:  PLoS One       Date:  2018-02-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.